億勝生物科技(01061.HK)獲批准在內地商業化不含防腐劑單劑量貝復舒滴眼液
格隆匯12月27日丨億勝生物科技(01061.HK)發佈公告,公司間接全資附屬公司珠海億勝生物製藥有限公司已取得國家藥品監督管理局批准於中國大陸註冊及商業化不含防腐劑單劑量貝復舒滴眼液。
獲批准產品為不含防腐劑單劑量貝復舒滴眼液產品,用於治療角膜上皮缺損、點狀角膜病變、複發性淺層點狀角膜病變、乾眼症、大泡性角膜炎、角膜擦傷等。
公告表示,獲批准產品預期快將推出市面。董事會相信,獲批准產品將提升患者對貝復舒系列產品之選擇範圍,以達致最佳治療效果。加入獲批准產品將增強集團於生長因子配方眼科藥物的競爭力及領導地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.